Get started
Author

Masahito Kotaka

Observed names: Kotaka M, Kotaka Masahito, Kotaka, M., Kotaka, Masahito, M. Kotaka, MASAHITO KOTAKA, Masahito KOTAKA
Institution: Sano Hospital
ORCID: 0000-0001-5976-613X
Observed ORCID: 0000-0001-5976-613X
OpenAlex ID: A5058315816
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
2023 · Daisuke Kotani, Eiji Oki, et al. · Nature Medicine · 521
PDF
ctDNA-based molecular residual disease and survival in resectable colorectal cancer
2024 · Yoshiaki Nakamura, Jun Watanabe, et al. · Nature Medicine · 262
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
2018 · Rui-Hua Xu, Kei Muro, et al. · The Lancet Oncology · 151
Early Results of Intersphincteric Resection for Patients with Very Low Rectal Cancer: An Active Approach to Avoid a Permanent Colostomy
2004 · Norio Saito, Masato Ono, et al. · Diseases of the Colon & Rectum · 136
Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer
2019 · Takayuki Yoshino, Takeharu Yamanaka, et al. · JAMA Oncology · 99
PDF
Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial)
2021 · Hideki Ueno, Megumi Ishiguro, et al. · British Journal of Cancer · 92
PDF
Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan.
2022 · Masahito Kotaka, Hiromichi Shirasu, et al. · Journal of Clinical Oncology · 63
Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
2020 · Hironaga Satake, Takeshi Kato, et al. · The Oncologist · 59
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
2020 · K. Yamazaki, T. Yamanaka, et al. · Annals of Oncology · 50
Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
2020 · Toshiki Masuishi, Akihito Tsuji, et al. · British Journal of Cancer · 48
PDF
Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY
2024 · K. Kataoka, K. Mori, et al. · Annals of Oncology · 45
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study
2018 · Eiji Oki, Takeshi Kato, et al. · Clinical Colorectal Cancer · 45
PDF
Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials
2016 · Yu Sunakawa, Wataru Ichikawa, et al. · Clinical Colorectal Cancer · 44
Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05)
2016 · Akihito Tsuji, Yu Sunakawa, et al. · Targeted Oncology · 40
Bladder-Sparing Extended Resection of Locally Advanced Rectal Cancer Involving the Prostate and Seminal Vesicles
2007 · Norio Saito, Takanori Suzuki, et al. · Surgery Today · 38
The addition of high magnifying endoscopy improves rates of high confidence optical diagnosis of colorectal polyps
2015 · Mineo Iwatate, Yasushi Sano, et al. · Endoscopy International Open · 37
PDF
A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11
2018 · Hironaga Satake, Yu Sunakawa, et al. · Oncotarget · 35
PDF
Prospective evaluation of the proportion of sessile serrated adenoma/polyps in endoscopically diagnosed colorectal polyps with hyperplastic features
2015 · Wataru Sano, Yasushi Sano, et al. · Endoscopy International Open · 35
PDF
Study of the intrahepatic surgical margin of hilar bile duct carcinoma.
2002 · Yasunaga Okazaki, Tadashi Horimi, et al. · PubMed · 34
Predictive Factors for Anastomotic Leakage after Simultaneous Resection of Synchronous Colorectal Liver Metastasis
2011 · Kentaro Nakajima, Shinichiro Takahashi, et al. · Journal of Gastrointestinal Surgery · 32
PDF
A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)
2019 · Takeshi Suzuki, Yasutaka Sukawa, et al. · Clinical Colorectal Cancer · 31
Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
2021 · Tatsuki Ikoma, Mototsugu Shimokawa, et al. · BMC Cancer · 30
PDF
Trifluridine/tipiracil plus bevacizumab as a first‐line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial
2020 · Eiji Oki, Akitaka Makiyama, et al. · Cancer Medicine · 29
PDF
Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer
2018 · Masahito Kotaka, Takeharu Yamanaka, et al. · ESMO Open · 28
Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)
2015 · Masahito Kotaka, Takayuki Yoshino, et al. · Cancer Chemotherapy and Pharmacology · 28
PDF
Works count: 256
Citation count: 2,732
H-index: 26
I10-index: 52
Year
Topic
Type